The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 329:1-7 July 1, 1993 Number 1
NextNext

Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors
Milton Packer, Mihai Gheorghiade, James B. Young, Peter J. Costantini, Kirkwood F. Adams, Robert J. Cody, L. Kent Smith, Lucy Van Voorhees, Lynn A. Gourley, M. King Jolly, for The RADIANCE Study

 Sign up for free e-toc
 

This Article
-Full Text

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice.

Methods We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed.

Results Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001) and body weight (P<0.001).

Conclusions These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.


Source Information

From the Mount Sinai School of Medicine, New York (M.P.); Henry Ford Hospital, Detroit (M.G.); Baylor College of Medicine, Houston (J.B.Y.); the University of Medicine and Dentistry of New Jersey, Camden (P.J.C.); the University of North Carolina, Chapel Hill (K.F.A.); Ohio State University School of Medicine, Columbus (R.J.C.); the Arizona Heart Institute, Tucson (L.K.S.); the Washington Hospital Center, Washington, D.{beta}(L.V.V.); G.H. Besselaar Associates, Princeton, N.J. (L.A.G.); and Burroughs Wellcome Co., Research Triangle Park, N.{beta}(M.K.J.).

Address reprint requests to Dr. Packer at the Division of Circulatory Physiology and Center for Heart Failure Research, Columbia University, College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032.

Full Text of this Article


Related Letters:

Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors
O'Mara N. B., Zimmerman W. B., Joffe I., Devereux R. B., Packer M., Gheorghiade M., Young J. B.
Extract | Full Text  
N Engl J Med 1993; 329:1819-1820, Dec 9, 1993. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.